Patents by Inventor Annabelle Gallois-Bernos
Annabelle Gallois-Bernos has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20240165019Abstract: The present invention relates to methods for treating tear film deficiencies in the eye by applying to the eye or the surrounding area a composition comprising hyaluronic acid.Type: ApplicationFiled: November 21, 2022Publication date: May 23, 2024Inventor: Annabelle Gallois-Bernos
-
Publication number: 20240165147Abstract: The present invention relates to methods for treating tear film deficiencies in the eye by applying to the eye or the surrounding area an oil in water emulsion composition, optionally comprising a demulcent such as a hyaluronic acid compound.Type: ApplicationFiled: November 21, 2022Publication date: May 23, 2024Inventor: Annabelle Gallois-Bernos
-
Patent number: 11311510Abstract: The present invention relates to ophthalmic compositions and methods for the treatment of dry eye and other inflammatory ocular conditions. In particular, the present invention relates to a composition comprising an esterified anti-inflammatory lipid mediator, which is an ester of an anti-inflammatory lipid mediator that is a reaction product of the anti-inflammatory lipid mediator and a polyol wherein the majority of the anti-inflammatory lipid mediator is present in an ester form. In this way, the compositions are substantially free of an acid form of the anti-inflammatory lipid mediators. Anti-inflammatory lipid mediators can be selected from the group consisting of polyunsaturated fatty acids (e.g., omega-three and omega-six fatty acids), resolvins or a metabolically stable analog, protectins or a metabolically stable analog, lipoxins or a metabolically stable analog, prostaglandins or a metabolically stable analog, retinoic acids, endocannabinoids, metabolites thereof, and mixtures thereof.Type: GrantFiled: February 13, 2020Date of Patent: April 26, 2022Assignee: Johnson & Johnson Vision Care, Inc.Inventor: Annabelle Gallois-Bernos
-
Publication number: 20210379005Abstract: The present invention relates to ophthalmic compositions and methods for the treatment of dry eye and other inflammatory ocular conditions. In particular, the present invention relates to a composition comprising an esterified anti-inflammatory lipid mediator, which is an ester of an anti-inflammatory lipid mediator that is a reaction product of the anti-inflammatory lipid mediator and a monohydric alcohol or an amide wherein the majority of the anti-inflammatory lipid mediator is present in an ester form. In this way, the compositions are substantially free of an acid form of the anti-inflammatory lipid mediators. Anti-inflammatory lipid mediators can be selected from the group consisting of polyunsaturated fatty acids (e.g.Type: ApplicationFiled: August 20, 2021Publication date: December 9, 2021Inventors: Annabelle Gallois-Bernos, Frank F. Molock, JR., Carrie L. Davis, Kathrine Osborn Lorenz, James K. Young, Kristy L. Canavan, Fang Lu
-
Patent number: 11096919Abstract: The present invention relates to ophthalmic compositions and methods for the treatment of dry eye and other inflammatory ocular conditions. In particular, the present invention relates to a composition comprising an esterified anti-inflammatory lipid mediator, which is an ester of an anti-inflammatory lipid mediator that is a reaction product of the anti-inflammatory lipid mediator and a monohydric alcohol or an amide wherein the majority of the anti-inflammatory lipid mediator is present in an ester form. In this way, the compositions are substantially free of an acid form of the anti-inflammatory lipid mediators. This composition can be topically delivered to the ocular surface via a preparation, solution, gel, ointment, and/or strip and/or a contact lens.Type: GrantFiled: July 2, 2019Date of Patent: August 24, 2021Assignee: Johnson & Johnson Vision Care, Inc.Inventors: Annabelle Gallois-Bernos, Frank F. Molock, Jr., Carrie L. Davis, Kathrine Osborn Lorenz, James K. Young, Kristy L. Canavan, Fang Lu
-
Publication number: 20200222357Abstract: The present invention relates to ophthalmic compositions and methods for the treatment of dry eye and other inflammatory ocular conditions. In particular, the present invention relates to a composition comprising an esterified anti-inflammatory lipid mediator, which is an ester of an anti-inflammatory lipid mediator that is a reaction product of the anti-inflammatory lipid mediator and a monohydric alcohol or an amide wherein the majority of the anti-inflammatory lipid mediator is present in an ester form. In this way, the compositions are substantially free of an acid form of the anti-inflammatory lipid mediators. Anti-inflammatory lipid mediators can be selected from the group consisting of polyunsaturated fatty acids (e.g.Type: ApplicationFiled: March 26, 2020Publication date: July 16, 2020Inventors: Annabelle Gallois-Bernos, Frank F. Molock, JR., Carrie L. Davis, Kathrine Osborn Lorenz, James K. Young, Kristy L. Canavan, Fang Lu
-
Publication number: 20200206178Abstract: The present invention relates to ophthalmic compositions and methods for the treatment of dry eye and other inflammatory ocular conditions. In particular, the present invention relates to a composition comprising an esterified anti-inflammatory lipid mediator, which is an ester of an anti-inflammatory lipid mediator that is a reaction product of the anti-inflammatory lipid mediator and a polyol wherein the majority of the anti-inflammatory lipid mediator is present in an ester form. In this way, the compositions are substantially free of an acid form of the anti-inflammatory lipid mediators. Anti-inflammatory lipid mediators can be selected from the group consisting of polyunsaturated fatty acids (e.g., omega-three and omega-six fatty acids), resolvins or a metabolically stable analog, protectins or a metabolically stable analog, lipoxins or a metabolically stable analog, prostaglandins or a metabolically stable analog, retinoic acids, endocannabinoids, metabolites thereof, and mixtures thereof.Type: ApplicationFiled: February 13, 2020Publication date: July 2, 2020Inventor: Annabelle Gallois-Bernos
-
Patent number: 10588887Abstract: The present invention relates to ophthalmic compositions and methods for the treatment of dry eye and other inflammatory ocular conditions. In particular, the present invention relates to a composition comprising an esterified anti-inflammatory lipid mediator, which is an ester of an anti-inflammatory lipid mediator that is a reaction product of the anti-inflammatory lipid mediator and a polyol wherein the majority of the anti-inflammatory lipid mediator is present in an ester form. In this way, the compositions are substantially free of an acid form of the anti-inflammatory lipid mediators. This composition can be topically delivered to the ocular surface via a preparation, solution, gel, ointment, and/or strip and/or a contact lens.Type: GrantFiled: August 22, 2014Date of Patent: March 17, 2020Assignee: Johnson & Johnson Vision Care, Inc.Inventor: Annabelle Gallois-Bernos
-
Publication number: 20190328698Abstract: The present invention relates to ophthalmic compositions and methods for the treatment of dry eye and other inflammatory ocular conditions. In particular, the present invention relates to a composition comprising an esterified anti-inflammatory lipid mediator, which is an ester of an anti-inflammatory lipid mediator that is a reaction product of the anti-inflammatory lipid mediator and a monohydric alcohol or an amide wherein the majority of the anti-inflammatory lipid mediator is present in an ester form. In this way, the compositions are substantially free of an acid form of the anti-inflammatory lipid mediators. This composition can be topically delivered to the ocular surface via a preparation, solution, gel, ointment, and/or strip and/or a contact lens.Type: ApplicationFiled: July 2, 2019Publication date: October 31, 2019Inventors: Annabelle Gallois-Bernos, Frank F. Molock, JR., Carrie L. Davis, Kathrine Osborn Lorenz, James K. Young, Kristy L. Canavan, Fang Lu
-
Patent number: 10383839Abstract: The present invention relates to ophthalmic compositions and methods for the treatment of dry eye and other inflammatory ocular conditions. In particular, the present invention relates to a composition comprising an esterified anti-inflammatory lipid mediator, which is an ester of an anti-inflammatory lipid mediator that is a reaction product of the anti-inflammatory lipid mediator and a monohydric alcohol or an amide wherein the majority of the anti-inflammatory lipid mediator is present in an ester form. In this way, the compositions are substantially free of an acid form of the anti-inflammatory lipid mediators. This composition can be topically delivered to the ocular surface via a preparation, solution, gel, ointment, and/or strip and/or a contact lens.Type: GrantFiled: June 13, 2012Date of Patent: August 20, 2019Assignee: Johnson & Johnson Vision Care, Inc.Inventors: Annabelle Gallois-Bernos, Frank F. Molock, Jr., Carrie L. Davis, Kathrine Osborn Lorenz, James K. Young, Kristy L. Canavan, Fang Lu
-
Patent number: 9801758Abstract: An apparatus for controlled healing of ocular erosions is described. The apparatus comprising; an optical surface comprising an energizable controller capable of being programmed to transmit energy from an energy source onto/into an ocular surface, through the use of a current generator in electrical connection with energy emitting contacts capable of transmitting an electric field. The controller, current generator and energy emitting contacts are biocompatible or encapsulated by a conductive biocompatible layer to allow positioning of said apparatus in an ocular surface.Type: GrantFiled: June 27, 2013Date of Patent: October 31, 2017Assignee: Johnson & Johnson Vision Care, Inc.Inventors: Randall Pugh, Annabelle Gallois-Bernos, Adam Toner, Andres Arrubla
-
Publication number: 20140364400Abstract: The present invention relates to ophthalmic compositions and methods for the treatment of dry eye and other inflammatory ocular conditions. In particular, the present invention relates to a composition comprising an esterified anti-inflammatory lipid mediator, which is an ester of an anti-inflammatory lipid mediator that is a reaction product of the anti-inflammatory lipid mediator and a polyol wherein the majority of the anti-inflammatory lipid mediator is present in an ester form. In this way, the compositions are substantially free of an acid form of the anti-inflammatory lipid mediators. This composition can be topically delivered to the ocular surface via a preparation, solution, gel, ointment, and/or strip and/or a contact lens.Type: ApplicationFiled: August 22, 2014Publication date: December 11, 2014Inventor: Annabelle Gallois-Bernos
-
Patent number: 8865685Abstract: The present invention relates to ophthalmic compositions and methods for the treatment of dry eye and other inflammatory ocular conditions. In particular, the present invention relates to a composition comprising an esterified anti-inflammatory lipid mediator, which is an ester of an anti-inflammatory lipid mediator that is a reaction product of the anti-inflammatory lipid mediator and a polyol wherein the majority of the anti-inflammatory lipid mediator is present in an ester form. In this way, the compositions are substantially free of an acid form of the anti-inflammatory lipid mediators. This composition can be topically delivered to the ocular surface via a preparation, solution, gel, ointment, and/or strip and/or a contact lens.Type: GrantFiled: June 13, 2012Date of Patent: October 21, 2014Assignee: Johnson & Johnson Vision Care, Inc.Inventor: Annabelle Gallois-Bernos
-
Publication number: 20140005514Abstract: An apparatus for controlled healing of ocular erosions is described. The apparatus comprising; an optical surface comprising an energizable controller capable of being programmed to transmit energy from an energy source onto/into an ocular surface, through the use of a current generator in electrical connection with energy emitting contacts capable of transmitting an electric field. The controller, current generator and energy emitting contacts are biocompatible or encapsulated by a conductive biocompatible layer to allow positioning of said apparatus in an ocular surface.Type: ApplicationFiled: June 27, 2013Publication date: January 2, 2014Inventors: Randall Pugh, Annabelle Gallois-Bernos, Adam Toner, Andres Arrubla
-
Publication number: 20130005691Abstract: The present invention relates to ophthalmic compositions and methods for the treatment of dry eye and other inflammatory ocular conditions. In particular, the present invention relates to a composition comprising an esterified anti-inflammatory lipid mediator, which is an ester of an anti-inflammatory lipid mediator that is a reaction product of the anti-inflammatory lipid mediator and a polyol wherein the majority of the anti-inflammatory lipid mediator is present in an ester form. In this way, the compositions are substantially free of an acid form of the anti-inflammatory lipid mediators. This composition can be topically delivered to the ocular surface via a preparation, solution, gel, ointment, and/or strip and/or a contact lens.Type: ApplicationFiled: June 13, 2012Publication date: January 3, 2013Inventor: Annabelle Gallois-Bernos
-
Publication number: 20130005805Abstract: The present invention relates to ophthalmic compositions and methods for the treatment of dry eye and other inflammatory ocular conditions. In particular, the present invention relates to a composition comprising an esterified anti-inflammatory lipid mediator, which is an ester of an anti-inflammatory lipid mediator that is a reaction product of the anti-inflammatory lipid mediator and a monohydric alcohol or an amide wherein the majority of the anti-inflammatory lipid mediator is present in an ester form. In this way, the compositions are substantially free of an acid form of the anti-inflammatory lipid mediators. This composition can be topically delivered to the ocular surface via a preparation, solution, gel, ointment, and/or strip and/or a contact lens.Type: ApplicationFiled: June 13, 2012Publication date: January 3, 2013Inventors: Annabelle Gallois-Bernos, Frank F. Molock, JR., Carrie L. Davis, Kathrine Osborn Lorenz, James K. Young, Kristy L. Canavan, Fang Lu